The IL-23/IL-17 axis as a therapeutic target

The IL-23/IL-17 axis as a therapeutic target.

T helper (Th) cells are known to differentiate into several distinct subsets depending on their environment. The Interleukin 17 (IL-17)-producing subset Th17, which was reported and named in 2005, has been extensively analyzed because a strong association with inflammatory disorders has been suggested. The condition in which Th17 cells are differentiated, critical transcription factors, and sim...

IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders.

IL-17 is a multifunctional cytokine produced by activated CD4+ and CD8+ lymphocytes as well as stimulated unconventional Tγδ and natural killer T cells. IL-17 induces expression of chemokines, proinflammatory cytokines and metalloproteinases, thereby stimulating the inflammation and chemotaxis of neutrophils. Elevation of proinflammatory cytokines is associated with asthma and autoimmune disord...

[Interleukin-17 as a therapeutic target in psoriasis].

Psoriasis is a chronic, immune-mediated inflammatory disease that affects up to 1-3% of the general population. An advanced understanding of the immune-pathogenesis of psoriasis has led to the development of new drugs that refine existing treatments or target novel molecular and immunologic pathways. IL-17 and Th17 cells play an important role in the pathogenesis of several autoimmune and immun...

The IL-23/IL-17 axis in inflammation.

IL-23 induces the differentiation of naive CD4(+) T cells into highly pathogenic helper T cells (Th17/Th(IL-17)) that produce IL-17, IL-17F, IL-6, and TNF-alpha, but not IFN-gamma and IL-4. Two studies in this issue of the JCI demonstrate that blocking IL-23 or its downstream factors IL-17 and IL-6, but not the IL-12/IFN-gamma pathways, can significantly suppress disease development in animal m...

The Role of IL-23/IL-17 Axis in Lupus